share_log

迈博药业-B(02181.HK):CMAB007(注射用奥马珠单抗α)的上市注册申请获批

Finet News ·  May 23, 2023 20:46

【财华社讯】迈博药业-B(02181.HK)公布,近日,公司核心产品之一,CMAB007(注射用奥马珠单抗α)的上市注册申请(NDA)获中国国家药品监督管理局批准,用于治疗确诊为免疫球蛋白E(“IgE”)介导的哮喘患者,为中国首个获国家药监局批准的国产过敏性哮喘治疗性抗体新药。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment